Tolcapone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using no specialized skill — this is a direct content-generation task with a fully specified template already provided; no coding, debugging, or brainstorming is required.
Tolcapone: From Parkinson's Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor, originally used as an adjunct to levodopa/carbidopa in Parkinson's disease. The TxGNN model's top-ranked prediction for this drug is Rasmussen Subacute Encephalitis, but this specific candidate currently has 0 clinical trials and 0 publications supporting it — the entire evidence base is the model score itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson's disease (adjunct to levodopa/carbidopa) — inferred from COMT-inhibitor classification cited in the evidence pack; no Norway market license on file to confirm approved wording |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the information available, Tolcapone is a COMT inhibitor used adjunctively with levodopa/carbidopa in Parkinson's disease, acting on catecholamine/dopamine metabolism.
Rasmussen encephalitis, however, is an autoimmune/inflammatory unilateral cortical disease with no established link to dopamine metabolism or the COMT pathway. The evidence pack's own rationale confirms this: there is no mechanistic connection, and no clinical trial or literature evidence exists for this pairing — it is purely a high TxGNN embedding-similarity score with no corroborating signal.
Notably, this same evidence pack contains two other candidates with clearer biological plausibility given Tolcapone's known pharmacology: Lewy body dementia (rank 6, L4, overlapping dopaminergic neurodegeneration) and juvenile parkinsonism / Hunt's paralysis agitans (rank 10, L4, mechanistically near-identical to the drug's core approved use). Neither has clinical trial or literature evidence in this dataset, but both merit consideration as more credible secondary hypotheses than the top-ranked score alone.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Currently no market authorization records in Norway — Tolcapone is not marketed in this territory.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Rasmussen subacute encephalitis) has no clinical, literature, or mechanistic support (Evidence Level L5), and the drug is not currently marketed in Norway. Critical safety data — TFDA warnings/contraindications (Blocking gap) and detailed MOA (High-severity gap) — are also missing, precluding even an initial safety screen.
To proceed, the following is needed:
- TFDA/regulatory package insert: warnings, contraindications (DG001)
- Detailed MOA data from DrugBank (DG002)
- If pursuing repurposing further, re-scope the candidate indication toward the higher-plausibility L4 signals in this dataset (Lewy body dementia, juvenile parkinsonism) rather than the top TxGNN score alone, and seek dedicated literature/trial searches for those specific indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.